Quinine News and Research

RSS

New approach to reduce gap between Western and traditional medicine

Scientists are reporting an advance toward overcoming a major barrier to tapping the potential of traditional Chinese medicine and India's Ayurvedic medicine in developing new and more effective modern drugs.

15 Mar 2013

CALHM1 protein plays critical role in sweet, bitter and umami taste perception

Working with a multidisciplinary consortium of 19 researchers from nine institutions, Monell scientists have provided critical information to identify CALHM1, a channel in the walls of taste receptor cells, as a necessary component in the process of sweet, bitter, and umami (savory) taste perception.

7 Mar 2013

Scientists demonstrate new approach for quickly assembling drug-like compounds

A team of scientists anchored at Yale University has demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment.

11 Feb 2013

Malaria vaccine trial: an interview with Professor Sir Brian Greenwood

Malaria is an infection caused by a parasite called plasmodium, which is transmitted from person to person by females of some species of mosquito. It is primarily a disease of tropical countries.

14 Dec 2012

Navigating the Labyrinth of Traumatic Brain Injury to Discover a Secondary Neurological Condition

Working with individuals with traumatic brain injury (TBI) every day, I see the debilitating effects and long-term struggles firsthand.

9 Oct 2012

Obesity affects taste in children, adolescents

Study results show that obese children perceive taste differently from their healthy weight peers, being significantly less able to identify the individual tastes of salty, umami, and bitter.

27 Sep 2012

Diet could avert toxic effects of quinine in patients with malaria

Scientists at The University of Nottingham say adverse side-effects caused by the anti-parasitic drug quinine in the treatment of malaria could be controlled by what we eat.

12 Sep 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

USPTO issues notice of allowance to Avanir for NUEDEXTA

Avanir Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA, further expanding the intellectual property portfolio for the company's lead commercial asset.

2 Jul 2012

Reducing off-label antipsychotic use may generate savings with little impact on patient care

Reducing the non-FDA-approved use of antipsychotic drugs may be a way to save money while having little effect on patient care, according to a Penn State College of Medicine study.

16 May 2012

New York Times examines history of malaria drug artemisinin

The New York Times examines the history of the Chinese drug artemisinin, "hailed as one of the greatest advances in fighting malaria ... since the discovery of quinine centuries ago," noting the drug "is being talked about as a candidate for a Nobel Prize in Medicine."

19 Jan 2012

New creative uses of DNA 'barcoding'

The newfound scientific power to quickly "fingerprint" species via DNA is being deployed to unmask quack herbal medicines, reveal types of ancient Arctic life frozen in permafrost, expose what eats what in nature, and halt agricultural and forestry pests at borders, among other applications across a wide array of public interests.

28 Nov 2011

Study outlines evolution of malaria, leishmaniasis and trypanosomiasis

One of the most comprehensive analyses yet done of the ancient history of insect-borne disease concludes for the first time that malaria is not only native to the New World, but it has been present long before humans existed and has evolved through birds and monkeys.

3 Nov 2011

Scientists identify distinct tobacco transporter for nicotine metabolism

A team of Virginia Tech and Purdue University scientists have identified a distinct transporter used by tobacco plant cells for nicotine metabolism. The research appears in the Oct. 17 online before print issue of the Proceedings of the National Academy of Sciences (PNAS) in the article, "A tobacco nicotine uptake permease effects alkaloid metabolism."

2 Nov 2011

Avanir seeks EMA marketing authorization for NUEDEXTA to treat pseudobulbar affect

Avanir Pharmaceuticals, Inc. announced today that it has submitted an application to the European Medicines Agency seeking marketing authorization for NUEDEXTA (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect.

31 Oct 2011

U.N. Secretary-General calls for scale up of global malaria efforts ahead of World Malaria Day

Global malaria control efforts must be significantly scaled up if the world is to reach the goal of reducing malaria deaths to almost zero by 2015, U.N. Secretary-General Ban Ki-moon said in a message on Thursday ahead of World Malaria Day, which is officially observed on Monday, the U.N. News Centre writes.

25 Apr 2011

MSF calls on African governments, WHO to switch to newer, more expensive treatment for severe malaria

Nearly 200,000 deaths from severe malaria could be averted if African governments replaced the low-cost antimalarial quinine with the more expensive but more effective drug artesunate, according to a report (.pdf) released Tuesday by Medicins Sans Frontieres (MSF), Reuters reports (Kelland, 4/19).

20 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Artesunate more effective against severe malaria

Quinine should no longer be the drug of choice for treating severe malaria, according to an updated systematic review by Cochrane researchers. It is now evident that the antimalarial drug artesunate, which is derived from herbs used in Chinese medicine, is more effective at preventing death in patients with severe malaria.

16 Mar 2011

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).

1 Feb 2011